The Technologies Dashboard provides a high-level overview of the technology landscape for neurodegenerative disease research and treatment. This page serves as a navigation hub for finding technologies by category, development stage, and therapeutic application. [1]
| Metric | Value |
|---|---|
| Total Technology Pages | 104 |
| AI/ML Tools | ~15 |
| Brain-Computer Interfaces | ~10 |
| Imaging Technologies | ~20 |
| Therapeutic Devices | ~15 |
| Research Tools | ~40 |
AI and machine learning technologies are transforming neurodegenerative disease research through improved diagnostic accuracy, prognostic modeling, and drug discovery.
Neural Network Architectures: Deep learning models including convolutional neural networks (CNNs) for image analysis, recurrent neural networks (RNNs) for time-series data, and transformer models for natural language processing. These architectures enable automated analysis of MRI scans, prediction of disease progression, and extraction of insights from electronic health records.
Machine Learning for Biomarker Discovery: ML algorithms identify patterns in multi-omic data (genomics, proteomics, metabolomics) to discover novel biomarkers for early diagnosis and disease monitoring. Support vector machines, random forests, and neural networks are commonly applied to distinguish disease states from healthy controls.
Natural Language Processing: NLP technologies extract structured information from scientific literature, clinical notes, and research papers to build knowledge graphs and assist literature review. See AI Literature Mining.
BCIs provide direct communication pathways between the brain and external devices, offering both diagnostic and therapeutic applications.
** Invasive BCIs**: Electrode arrays implanted in the motor cortex enable control of prosthetic limbs and computers. Companies like Neuralink and Synchron are developing implantable devices for patients with paralysis and movement disorders.
Non-Invasive BCIs: EEG-based BCIs and functional near-infrared spectroscopy (fNIRS) provide safer alternatives for research and clinical applications. These technologies are used for neurofeedback training and cognitive rehabilitation.
Neural Recording Technologies: High-density electrode arrays and emerging technologies like carbon fiber electrodes enable long-term recording of neural activity with single-neuron resolution. See Neural Recording.
Advanced imaging technologies enable visualization of brain structure, function, and molecular pathology.
Positron Emission Tomography (PET): PET imaging with amyloid and tau tracers enables in vivo visualization of protein pathology. New tracers for alpha-synuclein and neuroinflammation are in development. See PET Imaging.
Magnetic Resonance Imaging (MRI): Advanced MRI techniques including diffusion tensor imaging (DTI), functional MRI (fMRI), and magnetic resonance spectroscopy (MRS) provide insights into brain connectivity, activity, and metabolism. See MRI Technologies.
Optical Imaging: Two-photon microscopy enables visualization of neuronal activity and pathology in animal models. Label-free techniques like coherent anti-Stokes Raman scattering (CARS) detect protein aggregates without staining.
Deep Brain Stimulation (DBS): Implanted electrodes deliver electrical stimulation to specific brain regions, improving motor symptoms in Parkinson's disease and essential tremor. New closed-loop systems adapt stimulation based on neural activity. See Deep Brain Stimulation.
Transcranial Magnetic Stimulation (TMS): Non-invasive brain stimulation modulates cortical excitability. Repetitive TMS (rTMS) is being investigated for cognitive enhancement in Alzheimer's disease.
Focused Ultrasound: High-intensity focused ultrasound (HIFU) enables non-invasive lesioning of specific brain regions and targeted drug delivery across the blood-brain barrier.
NeuroWiki categorizes technologies by development stage using a modified technology readiness level (TRL) scale:
| TRL | Description | Examples |
|---|---|---|
| 1-3 | Basic research | Novel biomarkers, early AI models |
| 4-6 | Development | Clinical trials, FDA approvals |
| 7-9 | Deployment | Approved therapies, widespread adoption |
Optogenetics: Light-based control of neurons genetically modified to express light-sensitive ion channels. Currently limited to research but may enable precise neural circuit manipulation.
Gene Editing: CRISPR and other gene editing technologies enable correction of disease-causing mutations. Clinical trials for Huntington's disease and ALS are underway.
Cell Therapy: Stem cell-derived neurons and glial cells may replace lost cells and provide neurotrophic support. Clinical trials for Parkinson's disease are progressing.
Digital Therapeutics: Software-based interventions for cognitive training, symptom monitoring, and behavior modification. FDA-approved apps for Alzheimer's and Parkinson's are emerging.